AMCP Spring 2014

Day 1
Patrick Gleason, PharmD, Shares Prime Therapeutics' Approach to Specialty Drug Management
Patrick Gleason, PharmD, FCCP, BCPS, director of health outcomes, Prime Therapeutics, says his organization's primary goal is to get patients the medications they need, and to control costs by keeping premiums down.
Debbie Stern, RPh, Examines Current and Future Trends in Managing Specialty Pharmaceuticals
Debbie Stern, RPh, president, Rxperts, Inc, says that presently, there is an increasing focus on medical benefit management.
Partnering for New Distribution Channels for Specialty Pharmacy
The managed care industry is still struggling with the specialty pharmacy trend. The moderator of a session entitled New Specialty Pharmacy Distribution Channels, at The Academy of Managed Care Pharmacy's 26th Annual Meeting & Expo, started the discussion with a common complaint she hears from employers in 2014.
Specialty Pipeline: New Approvals Pending, More Management Awaits
Aimee Tharaldson, PharmD, senior clinical consultant, emerging therapeutics, Express Scripts, gave the health plan, PBM, and insurer attendees insight into the direction of specialty pharmacy approvals over the next few years, including the future of generics and biosimilars.
Day 2
Robert W. Dubois, MD, PhD, Discusses the ACO's Role in Proper Medication Management
Robert W. Dubois, MD, PhD, chief science officer, National Pharmaceutical Council, says that medications are integral to the management and success of accountable care organizations.
David Alain Wohl, MD, Discusses the Cost-Effectiveness of the Single-Tablet HIV Treatment
David Alain Wohl, MD, associate professor, division of infectious diseases, University of North Carolina at Chapel Hill, says cost-effectiveness of the single-tablet HIV regimen is debatable.
Integrating Pharmacists Into New Care Delivery Models
For the past few years, new care delivery models have evolved, spurred through innovation and, of course, new payment methods. The opportunities for pharmacists in these care delivery models are characterized by the spectrum of integration represented by the models themselves.
Affordable Care Act: Opportunities to Chart Your Course in the New Healthcare System
The Affordable Care Act is not going anywhere anytime soon, affirmed Scott Gottlieb, MD, a practicing physician and former Deputy Commissioner, US Food and Drug Administration.
Day 3
Dan Leonard Discusses the AMCP-ISPOR-NPC Comparative Effectiveness Research Collaboration
Dan Leonard, MA, president, National Pharmaceutical Council, says the AMCP-ISPOR-NPC comparative effectiveness research collaboration is an effort that supports data management.
Chuck Reynolds, MS, Describes the Role of CDHPs in Employer Health Benefits Strategy
Chuck Reynolds, MS, president, The Benfield Group, St Louis, Missouri, says consumer-directed health plans are important for employers, especially in light of the Affordable Care Act.
Payer Evidence Requirements for New Drugs: Trends and Impact
The call has been made-loud and clear: payers want more comparative evidence research (CER) for coverage decision making. However, the primary source for common research results-the biopharmaceutical industry-has been highly scrutinized by payers as a suitable source.
Early Experience With the Health Insurance Marketplaces
According to representatives of Milliman, the introduction of healthcare exchanges has been, for health plans, a harrowing experience.